These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21062081)

  • 1. Histamine H3 receptor as a drug discovery target.
    Berlin M; Boyce CW; Ruiz Mde L
    J Med Chem; 2011 Jan; 54(1):26-53. PubMed ID: 21062081
    [No Abstract]   [Full Text] [Related]  

  • 2. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
    Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
    Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Several down, a few to go: histamine H3 receptor ligands making the final push towards the market?
    Kuhne S; Wijtmans M; Lim HD; Leurs R; de Esch IJ
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1629-48. PubMed ID: 21992603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H3 receptor antagonists/inverse agonists as anti-obesity agents.
    Hancock AA
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1190-7. PubMed ID: 14649210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The histamine H(3) receptor: a target for new drugs].
    Arrang JM
    Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent medicinal chemistry of the histamine H3 receptor.
    Letavic MA; Barbier AJ; Dvorak CA; Carruthers NI
    Prog Med Chem; 2006; 44():181-206. PubMed ID: 16697898
    [No Abstract]   [Full Text] [Related]  

  • 7. Histamine-selective H3 receptor ligands and cognitive functions: an overview.
    Vohora D
    IDrugs; 2004 Jul; 7(7):667-73. PubMed ID: 15243869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
    Hancock AA
    Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
    Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
    Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders.
    Passani MB; Lin JS; Hancock A; Crochet S; Blandina P
    Trends Pharmacol Sci; 2004 Dec; 25(12):618-25. PubMed ID: 15530639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Possible roles of brain histamine H3 receptors and the pharmacology of its ligands].
    Onodera K; Watanabe T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Apr; 15(2):87-102. PubMed ID: 7796325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists.
    Hancock AA; Brune ME
    Expert Opin Investig Drugs; 2005 Mar; 14(3):223-41. PubMed ID: 15833055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.
    Schneider EH; Strasser A; Thurmond RL; Seifert R
    J Pharmacol Exp Ther; 2010 Aug; 334(2):513-21. PubMed ID: 20484153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
    Sadek B; Elz S; Pertz HH; Stark H; Schunack W
    Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in pharmacological properties of histamine H(3) receptor agonists and antagonists revealed at two human H (3) receptor isoforms.
    Esbenshade TA; Krueger KM; Yao BB; Witte DG; Estvander BR; Baranowski JL; Miller TR; Hancock AA
    Inflamm Res; 2006 Apr; 55 Suppl 1():S45-6. PubMed ID: 16705378
    [No Abstract]   [Full Text] [Related]  

  • 16. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
    Esbenshade TA; Fox GB; Cowart MD
    Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
    Hancock AA; Diehl MS; Fey TA; Bush EN; Faghih R; Miller TR; Krueger KM; Pratt JK; Cowart MD; Dickinson RW; Shapiro R; Knourek-Segel VE; Droz BA; McDowell CA; Krishna G; Brune ME; Esbenshade TA; Jacobson PB
    Inflamm Res; 2005 Apr; 54 Suppl 1():S27-9. PubMed ID: 15928821
    [No Abstract]   [Full Text] [Related]  

  • 18. Neuronal histamine and its receptors: implication of the pharmacological treatment of obesity.
    Masaki T; Yoshimatsu H
    Curr Med Chem; 2010; 17(36):4587-92. PubMed ID: 21062248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
    J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covalent Inhibition of the Histamine H
    Wágner G; Mocking TAM; Kooistra AJ; Slynko I; Ábrányi-Balogh P; Keserű GM; Wijtmans M; Vischer HF; de Esch IJP; Leurs R
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31835873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.